Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?

Vaccine

Department of Infectious Diseases, University College London Hospitals, London, UK; Mortimer Market Centre, Central & Northwest London NHS Foundation Trust, London, UK; The Francis Crick Institute, 1 Midland Road, London, UK; Division of Infection and Immunity, University College London, Gower Stree

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2025.127639DOI Listing

Publication Analysis

Top Keywords

offering hepatitis
4
hepatitis vaccination
4
vaccination vulnerable
4
vulnerable populations
4
populations plug
4
plug gaps?
4
offering
1
vaccination
1
vulnerable
1
populations
1

Similar Publications

Introduction: Hepatocellular carcinoma (HCC) remains a major cause of cancer mortality, and effective therapeutic options are limited. MicroRNA‑372‑3p (miR‑372‑3p) has been implicated in HCC, yet its exact role is unclear.

Methods: We established miR‑372‑3p‑overexpressing HCC cell lines (HepG2, SNU‑449, JHH‑4) via lentiviral transduction.

View Article and Find Full Text PDF

Encampment Medicine: Innovating Care Delivery in a Community of Tiny Shelters on Veterans Affairs Grounds.

Psychiatr Serv

September 2025

Center for the Study of Healthcare Innovation, Implementation, and Policy, Health Systems Research (HSR), U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles.

Veterans experiencing homelessness face barriers to traditional U.S. Department of Veterans Affairs (VA) care, even when temporarily housed on VA grounds.

View Article and Find Full Text PDF

A new frontier in oncology: Understanding the landscape of cancer vaccines.

J Oncol Pharm Pract

September 2025

Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.

Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.

View Article and Find Full Text PDF

Chronic liver disease (CLD) is a leading cause of global morbidity and mortality, necessitating effective preventive strategies. Growing evidence is linking coffee consumption with reduced risk of disease progression in various CLDs, including metabolic dysfunction associated steatotic liver disease (MASLD), alcoholic liver disease, hepatitis B and C, autoimmune hepatitis, and a reduction in the risk of hepatocellular carcinoma development. Coffee, a globally consumed beverage, contains bioactive compounds like caffeine, chlorogenic acids, diterpenes, and polyphenols, which may offer hepatoprotective benefits through anti-inflammatory, antioxidant, and metabolic regulatory effects.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a major global health issue, ranking as the sixth most common cancer and a leading cause of cancer-related deaths worldwide. Risk factors for HCC include chronic hepatitis B and C, obesity, alcohol abuse, diabetes, and metabolic disorders. Current treatments, such as surgery, transplantation, and chemotherapy, are often ineffective in advanced stages due to tumor resistance and the inability to target key oncogenic pathways.

View Article and Find Full Text PDF